Each year, over 3 million Europeans are diagnosed with cancer, and over 1 million Europeans die from the disease. With a growing and ageing population, action is urgently needed to address this major global health and societal concern. Action is needed to help policy-makers understand how they can improve access to innovative cancer care and treatment. Aim: To produce a policy white paper that summarised the major recommendations to improve access to innovative cancer care and treatment for Europeans diagnosed with cancer.
The European Cancer Patient Coalition developed the white paper over a one-year period, in collaboration with Interel Public Affairs, oncology experts, and the patient organisations that form the membership of the European Cancer Patient Coalition.
The “Value of Innovation in Oncology” white paper presented the position of the European Cancer Patient Coalition on innovation in oncology, and offered recommendations to help reduce variations in access to innovation and to involve patients in decision-making. It summarised the European Cancer Patient Coalition’s stance on topics related to innovation in oncology, with the overarching goal to shrink international variations in the time to patients’ access to innovation in oncology, while, at the same time, it considered the sustainability of health systems and how to ensure innovation is celebrated and accessed appropriately. Finally, the paper focused on recommendations to increase the involvement of patients in key aspects of innovation, including assessment and access.
More work is needed at the European and national level to improve the access of Europeans with cancer to innovative treatment and care and to ensure that people with cancer are actively involved in decisions throughout the care pathway.
Clinical trial identification
Legal entity responsible for the study
European Cancer Patient Coalition
Bristol-Myers Squibb, Eli Lilly and Company, MSD, Novartis, Pfizer, and Roche.
L. Makaroff, A. Rek, I. Manneh-Vangramberen, F. Florindi: Employee of the European Cancer Patient Coalition F. De Lorenzo: President of the European Cancer Patient Coalition K. Apostolidis: Vice President of the European Cancer Patient Coalition J. Pelouchova: Secretary of the European Cancer Patient Coalition A. Winterbottom: Treasurer of the European Cancer Patient Coalition S. Chrostowski, D. Cimpoeru, N. Bolanos Fernandez: Board member of the European Cancer Patient Coalition L. Baker: Employee of Interel Public Affairs Belgium. Clients of Interel Public Affairs include some pharmaceutical companies. The European Cancer Patient Coalition has received support from Merck, Pfizer, Roche, MSD, Bristol-Myers Squibb, AbbVie, Amgen, AstraZeneca, Baxter, BI, Celgene, Helsinn, Ipsen, Lilly, & Novartis.